SEC Filings | Landos Biopharma

Filing date	Form	Description	View
08/11/22	CORRESP	CORRESP	0001193125-22-218093.pdf 0001193125-22-218093.rtf 0001193125-22-218093.xls View HTML
05/16/22	CORRESP	CORRESP	0001193125-22-151650.pdf 0001193125-22-151650.rtf 0001193125-22-151650.xls View HTML
05/18/22	CORRESP	CORRESP	0001193125-22-153928.pdf 0001193125-22-153928.rtf 0001193125-22-153928.xls View HTML
04/25/24	DEFM14A	Definitive proxy statement relating to merger or acquisition	0001193125-24-114268.pdf 0001193125-24-114268.rtf 0001193125-24-114268.xls View HTML
07/24/20	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-20-007158.pdf 4.4 MB 0000950123-20-007158.rtf 0000950123-20-007158.xls View HTML
02/03/21	EFFECT	EFFECT	9999999995-21-000415.pdf 72.7 KB 9999999995-21-000415.rtf 9999999995-21-000415.xls View HTML
08/15/22	EFFECT	EFFECT	9999999995-22-002380.pdf 9999999995-22-002380.rtf 9999999995-22-002380.xls View HTML
02/16/21	SC 13D	Filing by person(s) reporting owned shares of common stock in a public company >5%	0001493152-21-004039.pdf 135.2 KB 0001493152-21-004039.rtf 0001493152-21-004039.xls View HTML
02/18/21	SC 13D	Filing by person(s) reporting owned shares of common stock in a public company >5%	0001193125-21-047859.pdf 359.3 KB 0001193125-21-047859.rtf 0001193125-21-047859.xls View HTML
02/04/21	424B4	Form of prospectus disclosing information facts events covered in both forms 424B1 424B3	0001193125-21-028952.pdf 7.5 MB 0001193125-21-028952.rtf 0001193125-21-028952.xls View HTML

Data provided by Kaleidoscope.